I was pleased to be able to share last evening with many of you at our third annual Yale Cancer Center Conclave. The highlight of the evening was the presentation of the Yale Cancer Center Lifetime Achievement, Clinical, Research, and Teaching prizes. The senior leadership team reviewed the nominations and selected the recipients of these awards in recognition of their outstanding contribution to cancer care and research.
Alan C. Sartorelli, PhD,
Alfred Gilman Professor of Pharmacology and former Director of Yale Cancer Center, was honored with the Yale Cancer Center Lifetime Achievement Award.
Alan Sartorelli, Joseph Bertino, and Thomas Lynch
The award was presented to Dr. Sartorelli by Dr. Joseph Bertino, the inaugural director of Yale Cancer Center and longtime friend and collaborator with Dr. Sartorelli. Ongoing research in Dr. Sartorelli's laboratory consists of several major areas concerned with the design, synthesis, and preclinical evaluation of newly conceived potential anti-neoplastic agents, with a particular focus on those that exert their anticancer effects. Dr. Sartorelli served as Chairman of the department of pharmacology at Yale from 1977-1984 and from 1998-2000 and Director of Yale Cancer Center from 1984-1993.
During his career, Dr. Sartorelli elucidated the concept of bioreductive activation of prodrugs by oxygen-deficient (hypoxic) tumor cells and synthesized and evaluated potential anticancer agents, contributing to our understanding of tumor cell metabolism. He was a co-founder of the Vion Pharmaceutical Company in New Haven and was a major leader in the development of several of their drugs. He was also an editor of Biochemical Pharmacology and executive editor of Pharmacology and Therapeutics. Dr. Sartorelli served on the editorial boards of many scientific journals, on many NIH committees, and mentored more than 100 graduate students and PhD candidates.
Richard Lifton, MD, PhD
received one of two 2011 Research Prizes for his paper
K+ Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
in the February 2011 issue of Science.
He is the Sterling Professor of Genetics and a member of the Yale Cancer Center Genetics and Genomics Research Program.
Daniel DiMaio, Richard Lifton, and Thomas Lynch
Ruth McCorkle, PhD was the recipient of the second 2011 Research Prize
for her paper
Healthcare Utilization in Women After Abdominal Surgery for Ovarian Cancerin the January/February issue of
Nursing Research.Ruth's research outcomes have continually improved patient care and supportive services for our patients. She is the director of the Psycho-Oncology Program at Yale Cancer Center, the Florence Wald Professor of Nursing, and a member of the Yale Cancer Center Cancer Prevention and Control Research Program.
Tish Knobf, Ruth McCorkle, Catherine Lyons,
and Thomas Lynch
Roy H. Decker, MD, PhD, Assistant Professor of Therapeutic Radiology, was honored with the 2011 Award for Clinical Excellence. Roy is an exceptional radiation oncologist and a wonderful model for the standards of patient care that we strive to have in place throughout Smilow Cancer Hospital. Over the last five years he has built our stereotactic radiotherapy program into one of the strongest programs in the country. "Roy puts clinical excellence and commitment to his patients first and foremost each day. He embodies the clinical excellence standards we have in place at Smilow Cancer Hospital," Lynn Wilson said in his remarks.
Roy Decker, Lynn Wilson, and Thomas Lynch
Also presented at the Conclave were the inaugural David S. Fischer Teaching Awards in recognition of outstanding teaching and mentoring of fellows at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven. Nominated by the fellows, Hari Deshpande, MD received the award for the Section of Medical Oncology and Nikolai Podoltsev, MD, PhD received the award for the Section of Hematology.
Roy Herbst and Hari Deshpande
Madhav Dhodapkar and Nikolai Podoltsev
National Accreditation for Breast Centers Site Visit Yale is set to become the first NCI-designated Comprehensive Cancer Center in the Northeast with a nationally accredited breast center. Over the past year, the team at the Breast Center - Smilow Cancer Hospital at Yale-New Haven has been working hard on developing organizational structure, evidence-based guidelines, and other quality improvement metrics to showcase our commitment to the highest quality of comprehensive interdisciplinary care for our patients with diseases of the breast. Few large cancer centers have subjected themselves to the rigorous evaluation required for accreditation through the National Accreditation Program for Breast Centers (NAPBC), and we are pleased to be one of the first to make the accreditation a priority. As part of this process, we will welcome Dr. Arnold Herman, a surveyor for the Commission on Cancer/NAPBC to Smilow on November 30 who will meet our leadership, tour our facilities, conduct a chart audit for compliance to quality metrics, and attend our breast conference.
Melanoma Institute of Australia Visits Smilow Members of the Melanoma Institute of Australia visited with the Melanoma Program at Smilow last week and attended Tumor Board to learn how to better integrate their program for multidisciplinary care. Dr. Jonathan Stretch, director of their program, scheduled the visit to allow his team to participate in a group tumor board and multidisciplinary care meeting so they can replicate our program in Australia.
Members of the Melanoma Institute of Australia and
Smilow Cancer Hospital's Melanoma Program
Correction from the November 11 Issue of DirectConnect:
The American Cancer Society elected 11 new officers to its volunteer 2010-2011 National Board of Directors. Vincent T. DeVita, Jr., MD, the Amy and Joseph Perella Professor of Medicine at Yale Cancer Center, was elected President Elect of the Board.
Michael Hurwitz and Hari Deshpande are participating in Movember!
For Movember, men start at the beginning of the month of November clean-shaven and grow mustaches to promote awareness of men's health and, specifically, of prostate cancer. Movember raises funds for the Livestrong Foundation and The Prostate Cancer Foundation. Please support their efforts through Team Smi-Mo.
The Employee Profile recognizes the diverse contributions made by Yale Cancer Center and Smilow Cancer Hospital staff have to meet our patient care, research, education, and outreach goals. The staff profiled are examples of the great work being done here, and the dedication and values we possess. To suggest someone to be profiled, please contact Emily Fenton
From managing departmental accounts, to grant submissions, Amy Ellis has a hand in a little bit of everything as an Accountant for Medical Oncology at Yale Cancer Center. Amy is responsible for making sure charging within the departments is done correctly, and she handles grant submissions for all of medical oncology; all while making sure things are done in a timely fashion.
For the grant submissions, Amy works with the PIs to create budgets, gathers information needed from other departments, and in collaboration with the Administrative Assistants, puts together the grant information and makes sure everything is accurate before submission. "It is great to see all of that hard work pay off when a grant is funded. You hope that it will make a difference for cancer patients, and in turn you feel like you have made a small difference in some way as well," said Amy.
Amy started at Yale as an Administrative Assistant working on the clinical side, but was looking for a challenge and a chance to grow. 6 years ago the opportunity arose for a position as a Financial Assistant at the Cancer Center and she took it, and shortly after was promoted to Accountant. Amy explained that the people she works with make her job easy and that she never gets bored with what she does.
Jennifer Mulligan, Associate Director of Finance and Administration commented, "Amy has been an integral member of the YCC Business Office team for the last six years. Her work with faculty developing grant budgets and assisting in the coordination of complex applications has shown her growth over this time frame. She has proven to be an invaluable member of the team. I see a great future for Amy in her dedication to her work and the Cancer Center as we grow."
2012 Connecticut Stem Cell Research Grants
The Connecticut Stem Cell Research Advisory Committee, in consultation with the Commissioner of the Department of Public Health and Connecticut Innovations, is pleased to announce the availability of the 2012 RFP to support the advancement of embryonic and/or human adult stem cell research in Connecticut.
Any non-profit, tax-exempt academic institution of higher education, any hospital that conducts biomedical research or any entity that conducts biomedical research or embryonic or human adult stem cell research may apply for grants from the Connecticut Stem Cell Research Fund. A one-page letter of intent to apply is due on December 2, 2011 by 4:30 PM, and may be submitted to Emily Smith.
Grants are awarded each year to researchers at medical schools recommended by the The Mary Kay Foundation Research Review Committee, which is composed of prominent doctors who volunteer their time to help the Foundation select the best recipients across the United States. After reviewing these recommendations, the Board of Directors at the Foundation selects the grant recipients.
$450,000 over 3 years + up to $100,000 of remaining medical school debt will be retired. For junior faculty with the MD or MD/PhD who are conducting patient-oriented cancer research and are capable of moving seamlessly between the laboratory and the patient's bedside in search of breakthrough treatments. Clinical research includes patient-oriented research, epidemiological and behavioral studies, outcomes research and health services research.
Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors. Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, Saltzman WM.
Drug Deliv Transl Res. 2011 Feb 1;1(1):34-42.
Read More >>
Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Cheng CJ, Saltzman WM.
Biomaterials. 2011 Sep;32(26):6194-203. Epub 2011 Jun 12.
Read More >>
C-path: a watson-like visit to the pathology lab. Rimm DL.
Sci Transl Med. 2011 Nov 9;3(108):108fs8.
Read More >>
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors. Zhou J, Patel TR, Fu M, Bertram JP, Saltzman WM.
Biomaterials. 2012 Jan;33(2):583-91. Epub 2011 Oct 19.
Read More >>
The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. Makarov DV, Desai RA, Yu JB, Sharma R, Abraham N, Albertsen PC, Penson DF, Gross CP.
J Urol. 2011 Nov 14.
Read More >>
Mycosis fungoides exhibiting features of a dermatofibroma: a case report and review of the literature. Morcos SM, Girardi M, Subtil A, Wilson LD, Cowper SE.
J Cutan Pathol. 2011 Nov 8. doi: 10.1111/j.1600-0560.2011.01804.x.
Read More >>
Using nodal ratios to predict risk of regional recurrences in patients treated with breast conservation therapy with 4 or more positive lymph nodes. Castrucci W, Lannin D, Haffty BG, Higgins SA, Moran MS.
ISRN Surg. 2011;2011:874814.
Read More >>
Postoperative calcium supplementation in patients undergoing thyroidectomy. Wang TS, Roman SA, Sosa JA.
Curr Opin Oncol. 2011 Nov 9.
Read More >>
Epigenetic impact of long-term shiftwork: pilot evidence from circadian genes and whole-genome methylation analysis. Zhu Y, Stevens RG, Hoffman AE, Tjonneland A, Vogel UB, Zheng T, Hansen J.
Chronobiol Int. 2011 Dec;28(10):852-61.
Read More >>
Punctate LC3B expression is a common feature of solid tumors and associated with proliferation, metastasis and poor outcome. Lazova R, Camp RL, Klump V, Siddiqui S, Amaravadi R, Pawelek JM.
Clin Cancer Res. 2011 Nov 11.
Read More >>
Treatment of Locally Advanced Pancreatic Cancer: The Role of Radiation Therapy. Johung K, Saif MW, Chang BW.
Int J Radiat Oncol Biol Phys. 2011 Nov 9.
Read More >>
Countdown to the CCSG Submission
until our CCSG
grant is due on
September 25, 2012.
Join Yale Cancer Center on Facebook
In the News
Read recent articles featuring experts from Yale Cancer Center.